Review: Neuroprotective Nanocarriers in Glaucoma.

Area of Science:

• Ophthalmology
• Neuroscience
• Materials Science

Background:

• Glaucoma is a leading cause of irreversible blindness, characterized by retinal ganglion cell (RGC) loss.
• Current treatments targeting intraocular pressure (IOP) are insufficient for many patients, necessitating new therapeutic strategies.
• Effective drug delivery to the eye is hindered by physiological barriers, limiting treatment efficacy.

Purpose of the Study:

• To review current nanotechnology-based approaches for glaucoma treatment.
• To explore the use of nanocarriers for delivering neuroprotective drugs to RGCs.
• To assess the potential of these advanced delivery systems in preventing RGC death and optic nerve degeneration.

Main Methods:

• Review of scientific literature on nanotechnology applications in glaucoma therapy.
• Analysis of studies combining neuroprotective agents with various nanocarrier systems.
• Evaluation of drug bioavailability and therapeutic outcomes in preclinical and clinical settings.

Main Results:

• Nanocarrier systems demonstrate enhanced penetration of ocular barriers, improving drug delivery to target tissues.
• Combination of neuroprotective drugs with nanocarriers shows potential in preventing RGC apoptosis and preserving optic nerve function.
• Non-invasive nanodelivery methods offer an alternative to invasive intravitreal injections, potentially reducing side effects.

Conclusions:

• Nanotechnology holds significant promise for developing novel, effective glaucoma treatments.
• Targeted delivery of neuroprotective agents via nanocarriers can mitigate RGC loss and slow disease progression.
• Further research into nanocarrier-based therapies is crucial for advancing glaucoma management and preventing blindness.